| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000036725 |
| Receipt No. | R000041816 |
| Scientific Title | Examination of influence that intake of test food gives to cognitive function |
| Date of disclosure of the study information | 2019/05/17 |
| Last modified on | 2019/12/13 (Ver. 4) |
| Basic information | ||
| Public title | Examination of influence that intake of test food gives to cognitive function-1
|
|
| Acronym | Examination of influence that intake of test food gives to cognitive function-1
|
|
| Scientific Title | Examination of influence that intake of test food gives to cognitive function
|
|
| Scientific Title:Acronym | Examination of influence that intake of test food gives to cognitive function
|
|
| Region |
|
|
| Condition | ||
| Condition | Healthy subjects
|
|
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The objective of this study was to investigate the effects of continuous intake of test foods on cognitive function of Japanese men and women who are aware of decline in cognitive function when they are 40 years of age or older.
|
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Cognitrax
Repeatable Battery for the Assessment of Neuropsychological Status |
| Key secondary outcomes | SF-36
Physical examination hematologic test blood biochemical test Urine analysis Adverse event |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | 12-weeks intake of the test food
|
|
| Interventions/Control_2 | 12-weeks intake of the placebo food
|
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Japanese male and female aged over 40 at the time of the informed consent.
2)Subject who is aware of cognitive decline. 3)Subject who is able to take the test food daily for 12 weeks. 4)Subject with an MMSE score of 24 or more. 5)Subject who has understood the purpose of the study, and agreed to participate it by signing the written informed consent. |
|||
| Key exclusion criteria | 1)Subject who is taking medication or under medical treatment.
2)Subject who is under exercise therapy or dietetic therapy. 3)Subject who has an allergy for test food. 4)Subject who has or had a history of either medicine or alcohol dependence syndrome. 5)Subject who has or had a history of mental illness (depression) or sleep disturbance. 6)Subject who is on a night-shift or is a shift worker. 7)Subject whose lifestyle is extremely irregular. 8)Subject who has an unbalanced diet. 9)Subject who is current disease or history of diabetes, liver disease (hepatitis), kidney disease, serious disease such as heart disease, thyroid disease, adrenal disease, other metabolic diseases. 10)Subject who is use health foods, supplements, and medicines(Icho-ha extract,DHA,EPA,Phosphatidylserine,lecithin etc) that may affect cognitive function. 11)Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study. 12)Subject who has blood drawn 200mL within the past 1 months or 400mL within the past 3 months from the day of the consent acquisition. 13)Subject who is planning to get pregnant after the day of informed consent or is currently pregnant and lactating. 14)Subject who can't keep the daily records. 15)Subject who is judged as an inappropriate candidate according to the screening data. 16)Subject who is considered as an inappropriate candidate by the doctor in charge. |
|||
| Target sample size | 60 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Pharma Foods International Co., Ltd.
|
||||||
| Division name | Development Department | ||||||
| Zip code | 615-8245 | ||||||
| Address | 1-49 Goryo-Ohara, Nishikyo-ku, Kyoto, Japan | ||||||
| TEL | 075-394-8605 | ||||||
| a-yamatsu@pharmafoods.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | HUMA R&D CORP | ||||||
| Division name | Clinical Development Division | ||||||
| Zip code | 108-0014 | ||||||
| Address | Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan | ||||||
| TEL | 03-3431-1260 | ||||||
| Homepage URL | |||||||
| ochitani@huma-rd.co.jp | |||||||
| Sponsor | |
| Institute | HUMA R&D CORP
|
| Institute | |
| Department | |
| Funding Source | |
| Organization | Pharma Foods International Co., Ltd.
|
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Ethics Committees of Nihonbashi Egawa Clinic |
| Address | 2F Kotobuki Build. 1-27-12 Yaesu Chuo-ku, Tokyo 103-0028 Japan |
| Tel | 03-5204-0311 |
| jim@medipharma.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 60 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | The dose of different from "Examination of influence that intake of test food gives to cognitive function-2". |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041816 |